ONCY

Company Overview — What Does ONCOLYTICS BIOTECH INC Do?

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada. ONCOLYTICS BIOTECH INC (ONCY) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Matthew C. Coffey and employs approximately 30 people, headquartered in ALBERTA CANADA, Alberta. With a market capitalization of $100M, ONCY is one of the notable companies in the Healthcare sector.

ONCOLYTICS BIOTECH INC (ONCY) Stock Rating — Reduce (April 2026)

As of April 2026, ONCOLYTICS BIOTECH INC receives a Reduce rating with a composite score of 38.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ONCY ranks #2,972 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ONCOLYTICS BIOTECH INC ranks #424 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ONCY Stock Price and 52-Week Range

ONCOLYTICS BIOTECH INC (ONCY) currently trades at $1.00. The stock lost $0.04 (3.8%) in the most recent trading session. The 52-week high for ONCY is $1.51, which means the stock is currently trading -33.8% from its annual peak. The 52-week low is $0.33, putting the stock 206.9% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is ONCY Overvalued or Undervalued? — Valuation Analysis

ONCOLYTICS BIOTECH INC (ONCY) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 21.76x, versus the sector average of 2.75x.

At current multiples, ONCOLYTICS BIOTECH INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ONCOLYTICS BIOTECH INC Profitability — ROE, Margins, and Quality Score

ONCOLYTICS BIOTECH INC (ONCY) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -2120.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1517.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ONCY Debt, Balance Sheet, and Financial Health

ONCOLYTICS BIOTECH INC has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.12x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $11M.

ONCY has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ONCOLYTICS BIOTECH INC is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ONCOLYTICS BIOTECH INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, ONCOLYTICS BIOTECH INC reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-29M. Operating income came in at $-29M.

In FY 2025, ONCOLYTICS BIOTECH INC reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-29M. Operating income came in at $-29M.

In FY 2024, ONCOLYTICS BIOTECH INC reported revenue of $0 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-22M. Operating income came in at $-24M.

In FY 2023, ONCOLYTICS BIOTECH INC reported revenue of $0 and earnings per share (EPS) of $-0.41. Net income for the quarter was $-21M. Operating income came in at $-26M.

Over the past 8 quarters, ONCOLYTICS BIOTECH INC has experienced revenue contraction from $0 to $0. Investors analyzing ONCY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ONCY Dividend Yield and Income Analysis

ONCOLYTICS BIOTECH INC (ONCY) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ONCY Momentum and Technical Analysis Profile

ONCOLYTICS BIOTECH INC (ONCY) has a momentum factor score of 52/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 61/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

ONCY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ONCOLYTICS BIOTECH INC (ONCY) ranks #424 out of 838 stocks based on the Blank Capital composite score. This places ONCY in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ONCY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ONCY vs S&P 500 (SPY) comparison to assess how ONCOLYTICS BIOTECH INC stacks up against the broader market across all factor dimensions.

ONCY Next Earnings Date

No upcoming earnings date has been announced for ONCOLYTICS BIOTECH INC (ONCY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ONCY? — Investment Thesis Summary

The quantitative profile for ONCOLYTICS BIOTECH INC suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. High volatility (stability score 34/100) increases portfolio risk.

In summary, ONCOLYTICS BIOTECH INC (ONCY) earns a Reduce rating with a composite score of 38.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ONCY stock.

Related Resources for ONCY Investors

Explore more research and tools: ONCY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ONCY head-to-head with peers: ONCY vs AZN, ONCY vs SLGL, ONCY vs VMD.